Several lines of evidence support the hypothesis that impaired function of the glutamatergic N-methyl-D-aspartate receptor (NMDAR) might be involved in the aetiology of schizophrenia. NMDAR is activated by phosphorylation by Fyn and there is also some evidence to suggest that abnormalities in Fyn functionality could also be involved in susceptibility to schizophrenia. In a recent weighted burden analysis of exome sequenced schizophrenia cases and controls we noted modest statistical evidence for an enrichment of rare, functional variants in FYN, GRIN1 and GRIN2B in schizophrenia cases.
Introduction
Outside of the cerebellum, the glutamatergic N-methyl-D-aspartate receptor (NMDAR) consists of a tetramer of two NR1 subunits, coded for by the gene GRIN1, and two NR2 units, either NR2A or NR2B, coded for by GRIN2A and GRIN2B (Chen and Roche, 2007) . Variants in these genes can lead to with epilepsy, intellectual disability and other neuropsychiatric disorders (XiangWei, Jiang and Yuan, 2018) . As recently reviewed, there is evidence from a variety of sources to support the hypothesis that hypofunction of NMDAR may contribute to the pathophysiology of schizophrenia (Balu, 2016) . Phencyclidine, which is an NMDAR channel blocker, induces a psychotomimetic state that closely resembles schizophrenia and can produce not only positive symptoms of hallucinations and delusions but also formal thought disorder and negative symptoms (Javitt and Zukin, 1991) . Some studies have found reduced levels of GRIN1 mRNA and/or NRl protein in different brain regions of subjects with schizophrenia (Gao et al., 2000; Law and Deakin, 2001; Stan et al., 2015; Catts et al., 2016) . Patients with autoimmune NMDAR encephalitis can present with psychotic symptoms, memory deficits and catatonic symptoms (Dalmau et al., 2011) and patients with an initial diagnosis of schizophrenia are reported to have increased rates of NMDAR antibodies (Steiner et al., 2013) . GRIN2A was included in one of the 108 implicated regions in a large genome-wide association study of schizophrenia (Schizophrenia Working Group of the Psychiatric Genomics Consortium, 2014) and the set of genes coding for proteins associated with NMDAR was found to be enriched for both de novo copy number variants (CNVs) and small de novo mutations (Kirov et al., 2012; Fromer et al., 2014) . In the Swedish schizophrenia study including nearly 5000 exome-sequenced schizophrenia cases there was an enrichment of ultra-rare, singleton variants predicted to be gene-disruptive among the set of genes encoding interactors with NMDAR (Genovese et al., 2016) .
A fundamental mechanism for regulating NMDAR function is by phosphorylation, which affects both the trafficking of the receptor and its channel properties, as has been reviewed in detail elsewhere (Chen and Roche, 2007) . The subunits contain many serine/threonine phosphorylation sites which are substrates for protein kinases A, B and C (PKA, PKB and PKC), calcium/calmodulin-dependent protein kinase II (CaMKII) and casein kinase II (CKII). Phosphorylation of these sites can have a variety of effects on the pharmacological functioning of NMDAR. Separately, the subunits also contain tyrosine residues which are substrates for phosphorylation by protein tyrosine kinases, in particular Fyn and Src, and this can affect NMDAR function as well as trafficking and endocytosis so that tyrosine phosphorylation by these kinases serves to upregulate NMDAR (Ali and Salter, 2001) . The Tyr 1325 residue of NR2A is most prominently phosphorylated in vitro by Fyn and mice engineered to have a homozygous Tyr-1325-Phe mutation to prevent the phosphorylation of this site are reported to show some antidepressant-like behaviour (Taniguchi et al., 2009 ). Fyn deficient mice show an increased acoustic startle response under bright light and this is accompanied by increased serotonergic and dopaminergic activity in the prefrontal cortex and limbic system (Hironaka, Yagi and Niki, 2002) . Haloperidol injection activates Fyn in mice and increases NR2B phosphorylation while Fyn deficient mice are resistant to haloperidol-induced catalepsy (Hattori et al., 2006) . Alternative mRNA splicing with lower levels of Fyn protein has been reported to occur in schizophrenia cases and their relatives (Hattori et al., 2009) and in a recent GWAS of schizophrenia rs7757969, which lies in an intron of FYN, the gene which codes for Fyn, was significant at p = 4.8 × 10 −8 (Li et al., 2017) . Of note, Fyn itself is subject to phosphorylation and is activated by autophosphorylation of a conserved residue, tyrosine 416 (Y416), a process which is subject to dopaminergic and cholinergic regulation (Mao and Wang, 2015) .
We carried out an analysis of the exome-sequenced Swedish schizophrenia cases and controls but in contrast to the previously reported study (Genovese et al., 2016) we did not restrict attention to only singleton variants predicted to completely disrupt gene-functioning but we included all rare variants, though with a weighting scheme to give higher weight to variants predicted to have a more deleterious effect (Curtis et al., 2018) . For this weighted burden analysis the strength of evidence implicating each gene is summarised as the signed log p value (SLP) and we noted that the set of genes with most evidence for an excess of rare, damaging variants in schizophrenia cases was the set denoted "FMRP targets" (gene set SLP = 7.1) and that within this set the most strongly implicated gene was FYN, with SLP = 3.4. Other genes within this set included GRIN1 (SLP = 1.7) and GRIN2B (SLP = 2.1).
These results suggested to us the possibility that genetic variants might increase susceptibility to schizophrenia by impairing the normal functioning of NMDAR through different mechanisms. This might be through variants within the genes coding for the NMDAR subunits or through variants in genes such as FYN whose products would normally upregulate NMDAR. Such variants might completely disrupt the functioning of the gene, by producing stop codons, frameshifts or splice site changes. Alternatively they might introduce amino acid changes which critically affected the functioning of the protein. In particular, a coding variant changing a tyrosine residue which was a target of Fyn might have a similar effect to a deleterious variant in FYN itself. Accordingly we decided to investigate more closely the coding variants occurring in genes for the NMDAR subunits and the kinases acting on them.
Methods
We used the results from the previously reported weighted burden analysis of exomesequenced Swedish subjects consisting of 4225 schizophrenia cases and 5834 controls (Curtis et al., 2018) . We restricted attention to the genes which code for the subunits of the NMDAR protein and the kinases which are involved in its phosphorylation, as listed in Table  1 . Variants were annotated with using VEP, PolyPhen and SIFT (Kumar, Henikoff and Ng, 2009; Adzhubei, Jordan and Sunyaev, 2013; McLaren et al., 2016) . We restricted attention to variants which were both rare, occurring in a total of no more than 10 subjects, and predicted either to completely disrupt gene functioning (frameshift, stop-gained and essential splice site variants) or to be potentially damaging, defined as being non-synonymous variants predicted as deleterious by SIFT and/or as possibly or probably damaging by PolyPhen. Population frequencies for all variants studied were obtained from gnomAD (Lek et al., 2016) . For the damaging variants, we visualised the distribution of the altered amino acid residues across functional domains of the protein using the ProteinPaint web application provided at https://pecan.stjude.cloud/home (Zhou et al., 2016) . In order to assess whether damaging variants might disrupt phosphorylation sites we used the information provided by PhosphoSitePlus (Hornbeck et al., 2015) . For each protein, this provides information regarding which residues are subject to phosphorylation and other modifications along with the number of references which support this modification from highthroughput and low-throughput experiments, the latter being more reliable. For the assessment of the possible impact of variants on phosphorylation sites we restricted attention to tyrosine residues in the NMDAR subunits and Fyn. In order to visualise the distribution of altered amino acid residues in the 3D structure of the protein we obtained structures from the RCSB Protein Data Bank at www.rcsb.org (Berman et al., 2000) and colour-coded altered residues using the JSmol viewer provided there. Since the preliminary results did not suggest that disturbance of serine-threonine kinase functioning was associated with schizophrenia, for the 3D studies we restricted investigation to NMDAR, Fyn and Src. Table 2 shows the summary results for the genes involved as obtained from the original weighted burden analysis. This shows that GRIN1, GRIN2B and FYN have modestly positive SLP values. In this analysis, three disruptive mutations had been assigned to GRIN2B. However on further examination it transpired that there was a single frameshift mutation in one subject but that this had been annotated as three separate frameshift mutations close to each other. Once this was corrected there was one case and one control with a disruptive variant in GRIN2B and no excess of damaging variants in cases. 2 cases and no controls had a disruptive variant in FYN and both GRIN1 and FYN had an excess of damaging variants in cases. Of note, although GRIN2A produced only a very small SLP in the weighted burden analysis (0.14), three cases and no controls had a disruptive variant in this gene. By contrast, SRC had an excess of damaging variants in controls and overall there was no suggestion that there was an excess of rare disruptive and damaging variants in cases in the genes coding for the serine-threonine kinases. Table 3 shows a detailed breakdown of the amino acid changes in GRIN1, GRIN2A, GRIN2B and FYN.
Results
As shown in Figure 1 and Supplementary Figure 1 , for almost all genes the distribution of damaging variants across protein domains did not reveal any particular patterns and there was no marked tendency for a specific functional domain to be enriched for damaging variants in cases. NR1 has an excess of damaging variants in cases and these are widely distributed The only gene to show a pattern in the distribution of damaging variants was Fyn. As shown in Figure 1d and Supplementary Figure 1d , the three amino acid residues altered in controls all occurred in the N-terminal region of the protein to which no functional domain is assigned. By contrast, ten cases had a genetic variant which would alter an amino acid residue in one of the functional domains.
With regard to phosphorylation sites, experimental support for each site can be quantified by the number of supporting references (high throughput / low throughput). The best supported site in NR2A is Y943 (134/2) and one case has a Y943C variant. In NR2B three cases and two controls have Y1371C but this site has only modest support (11/1). One control has a Y30C substitution in Fyn but this site has only low support (0/1). No other well supported sites were directly affected. However it may be worth noting that there two well supported sites adjacent to each other in Fyn, Y213 (1800/1) and Y214 (671/1), and that three cases have a T216S substitution. It is not inconceivable that this change two residues away might be sufficient to disrupt recognition of the site and hence impair phosphorylation.
In general, examination of the 3D localisation of the substitutions did not yield any new insights. However using model 2DQ7 (Kinoshita et al., 2006) for Fyn did reveal that A376T (observed in two cases) and Q517E (observed in one case) end up adjacent to each other in the folded protein. This is illustrated in Supplementary Figure 2 .
On examining the distribution of variants across subjects in GRIN1, GRIN2A, GRIN2B and FYN, it emerged that one case had a damaging variant in GRIN1 and a frameshift variant in GRIN2A while another subject had a damaging variant in GRIN1 and in GRIN2B. No other subject had more than one variant in these genes.
Discussion
The number of variants involved is too small for any definite conclusions to be reached. However there are a few points of interest. Firstly, there is no evidence to implicate disruption of serine-threonine phosphorylation or disruption of tyrosine phosphorylation by Src. Thus, if impaired tyrosine phosphorylation of NMDAR has any relevance to schizophrenia aetiology this seems likely to be specific to Fyn rather than Src. It is also not the case that amino acid substitutions in NMDAR preventing phosphorylation occur commonly in schizophrenia -we observe this in only a single case out of 4225. Nor is there strong evidence that variants interfering with Fyn autophosphorylation occur commonly. We see no definite examples of this and the closest we come to any support for this is the observation that three cases have an amino acid substitution two residues away from a tyrosine residue which is well supported as a phosphorylation site. We do observe that 3 cases and no controls have disrupting variants in GRIN2A and that 8 cases and 1 control have damaging variants in GRIN1. 14 cases and 3 controls have damaging variants in FYN but if we restrict attention to functional domains of the protein this applies to 10 cases and no control. Aside from that, we cannot discern any obvious pattern to the distribution of damaging variants. Overall, these possibly relevant variants were seen in about 0.5% of the cases.
These results are perfectly consistent with the hypothesis that the risk of schizophrenia may be increased by genetic variants impairing NMDAR functioning either directly or by reducing phosphorylation by Fyn. However this study provides at best only modest further support. It is hoped that the situation may become clearer as larger numbers of cases are sequenced. It might also be helpful to carry out functional studies to determine the effect of these variants in vitro and in vivo. This approach demonstrates ways in which additional information of possible biological relevance can be mined from sequencing studies.
Table 1
Genes for the NMDAR protein and the kinases involved in its phosphorylation.
Protein
Gene(s) Glutamatergic NMDA receptor (NMDAR) GRIN1, GRIN2A, GRIN2B Protein kinase A (PKA) PRKACA, PRKACB, PRKACG, PRKAR1A, PRKAR1B, PRKAR2A, PRKAR2B Protein kinase C (PKC) PRKCA, PRKCB, PRKCG Protein kinase B (PKB) PTK2B Calcium/calmodulin-dependent protein kinase II (CaMKII) CAMK2A, CAMK2B, CAMK2G, CAMK2D Casein kinase II (CKII) CSNK2A1, CSNK2A2, CSNK2B Proto-oncogene tyrosine-protein kinase Fyn FYN Proto-oncogene tyrosine-protein kinase Src SRC Table 2 Results obtained from original weighted burden analysis for genes coding for NMDAR and the kinases acting on it. The SLP is the signed log p value, indicating the overall level of support for association with schizophrenia obtained from the weighted burden analysis. For rare variants, occurring in no more than ten subjects, the total counts for gene-disruptive and gene-damaging variants in controls and cases is shown. Variants from each gene in the relevant transcript as displayed by ProteinPaint. Variants seen in cases are coloured black while variants seen in controls are coloured grey. Where more than one case or one control has the same variant the number possessing it is shown within the circle and the size of the circle is increased proportionately.
(a) GRIN1 variants affecting NR1 (b) GRIN2A variants affecting NR2A (c) GRIN2B variants affecting NR2B
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Supplementary Figure 1
Variants from each gene in the relevant transcript as displayed by ProteinPaint. Variants seen in cases are coloured black and in the key labelled "NONSTANDARD" while variants seen in controls are coloured grey and labelled "PROTEINDEL". Where more than one case or one control has the same variant the number possessing it is shown within the circle and the size of the circle is increased proportionately.
